Korean J Urol Oncol.  2018 Dec;16(3):97-102. 10.22465/kjuo.2018.16.3.97.

Precision Medicine in Castration-Resistant Prostate Cancer

  • 1Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea. sjyun@chungbuk.ac.kr, wjkim@chungbuk.ac.kr
  • 2Department of Urology, Chungbuk National University Hospital, Cheongju, Korea.


Prostate cancer is usually managed by androgen deprivation therapy after failure of primary treatment. However, such therapies are only temporarily effective in prostate cancer patients, and the most patients experience the progression to castration-resistant prostate cancer (CRPC). Docetaxel chemotherapy is conventional effective treatment for CRPC but has many adverse effects. In CRPC patients, treatment decisions were not typically base on the recognitions of inter-individual differences. Therefore, there are growing interests for precision medicine in CRPC. In this review, we summarized the precision medicine such as candidate target genes and potential therapies in CRPC.


Prostatic neoplasms; Precision medicine; Prostatic neoplasms; Castration-resistant
Full Text Links
  • KJUO
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr